Case study recording
Duration: 5 minutes
Antibody Drug Conjugates (ADCs) are fulfilling their promise as a new therapeutic class for the treatment of cancer.
However, ADCs are complex multicomponent molecules presenting unique manufacturing challenges.
In this case study, our expert Bertrand Cottineau explains how his team conducted process and analytical development to support Phase 1 cGMP manufacture of a maleimide cysteine based ADC.
What you will learn
- The project background and challenges
- The solution proposed by Novasep to answer customer needs: process development carried out and analytical methods developed
- The results
Bertrand Cottineau, Ph.D., PR&D group head (highly potent chemistry and bioconjugation), Novasep Le Mans, France. He completed a Ph.D. degree in organic chemistry at Orleans University in 2002. He has more than 15 years’ experience in process development for API and contributed to 9 scientific publications in international journals. He joined Novasep Le Mans in 2013 to lead the HPAPI process development group and is now responsible for both HPAPI and bioconjugation process development groups.
It's time to learn more about the process and analytical development of a maleimide cysteine based ADC!
To watch this case study recording, just fill the form below: